Arnett DK, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 74:1376–1414.
Sharp Collaborative Group. Study of Heart and Kidney Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010; 160:785–794.
Major RW, et al. Statins and cardiovascular primary prevention in CKD: a meta-analysis. Clin J Am Soc Nephrol 2015; 10:732–739.
Huang TM, et al. Effects of statin use in advanced chronic kidney disease patients. J Clin Med 2018; 7(9). doi: 10.3390/jcm7090285.
Palmer SC, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 2012; 157:263–275.
Herrington WG, et al. Impact of kidney function on the effects of LDL cholesterol lowering with statin-based regimens: A meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4:829–839.
Reiss AB, et al. Cholesterol metabolism in non-diabetic chronic kidney disease. Am J Kidney Dis 2015; 66:1071–1082.
Navaneethan SD, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; (2):CD007784.
Chung CM, et al. Effects of statin therapy on cerebrovascular and kidney outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. J Clin Lipidol 2017; 11:422–431.e2.
Chang CH, et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis 2014; 232:224–230.